Artikel ; Online: Potential treatment option of rivaroxaban for breastfeeding women: A case series.
2024 Band 237, Seite(n) 141–144
Abstract: The use of direct oral anticoagulants (DOACs) in breastfeeding women is currently challenging due to limited safety data for breastfeeding infants, and there have been no previous studies on the drug concentration in breastfeeding infants. We treated 2 ... ...
Abstract | The use of direct oral anticoagulants (DOACs) in breastfeeding women is currently challenging due to limited safety data for breastfeeding infants, and there have been no previous studies on the drug concentration in breastfeeding infants. We treated 2 patients (one case was twin pregnancy) with venous thromboembolisms in breastfeeding women administered rivaroxaban at our institution. Blood samples from the mothers and breastmilk samples were collected at time 0 and 2 h after the rivaroxaban administration, breastfeeding was conducted 2 h after the rivaroxaban administration, and blood samples from the infants were collected 2 h after breastfeeding (4 h after maternal rivaroxaban administration). The milk-to-plasma (M:P) ratios were 0.27 in Case 1 and 0.32 in Case 2. The estimated relative infant dose (RID) was 0.82 % in Case 1 Children 1 and 2, and 1.27 % in Case 2. The rivaroxaban concentration in the infant plasma was below the lower limit of quantification in all infants. In addition, even in the high-exposure case simulation based on 5 days of breastfeeding in Case 2, the infant plasma concentration level was below the lower limit of quantification. At 3 months of follow-up, breastfeeding was continued, and all infants grew and developed without any health problems including bleeding events. The current case series showed that there were no pharmacokinetic or clinical concerns for breastfeeding women or breastfed infants, and provides support for rivaroxaban as a safe treatment option for these patients. |
---|---|
Mesh-Begriff(e) | Humans ; Rivaroxaban/therapeutic use ; Rivaroxaban/pharmacokinetics ; Female ; Breast Feeding ; Adult ; Factor Xa Inhibitors/therapeutic use ; Factor Xa Inhibitors/pharmacokinetics ; Milk, Human/chemistry ; Milk, Human/metabolism ; Infant ; Venous Thromboembolism/drug therapy ; Infant, Newborn ; Pregnancy |
Chemische Substanzen | Rivaroxaban (9NDF7JZ4M3) ; Factor Xa Inhibitors |
Sprache | Englisch |
Erscheinungsdatum | 2024-04-05 |
Erscheinungsland | United States |
Dokumenttyp | Case Reports ; Journal Article ; Letter |
ZDB-ID | 121852-9 |
ISSN | 1879-2472 ; 0049-3848 |
ISSN (online) | 1879-2472 |
ISSN | 0049-3848 |
DOI | 10.1016/j.thromres.2024.04.003 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 863: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.